REGNSame old biotech drama, new legal wrapper
Regeneron is back in the spotlight, and not for the fun kind of biotech headline. Levi & Korsinsky says it’s investigating securities claims against the company after Regeneron disclosed on May 16th that its Phase 3 melanoma trial for fianlimab combined with Libtayo missed the primary endpoint versus Merck’s Keytruda.
That kind of miss is basically the biotech version of tripping at the finish line. The market was already upset by the clinical failure, and now the lawyers are sniffing around too — which tends to keep pressure on the shares and the narrative.
Why investors care
For Regeneron, this isn’t just a science problem. It’s a business problem, because oncology data can shape:
- future label-expansion hopes
- physician adoption expectations
- peak-sales models for the combo
- and, apparently, the size of the plaintiff bar’s afternoon coffee budget
Big picture
If the trial miss was the punch to the jaw, the investigation is the awkward second shoe dropping. Investors usually don’t love that combo.